Last reviewed · How we verify
[18F]MNI-1054
[18F]MNI-1054 is a Small molecule drug developed by Invicro. It is currently in Phase 1 development.
At a glance
| Generic name | [18F]MNI-1054 |
|---|---|
| Sponsor | Invicro |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [18F]MNI-1054 CI brief — competitive landscape report
- [18F]MNI-1054 updates RSS · CI watch RSS
- Invicro portfolio CI
Frequently asked questions about [18F]MNI-1054
What is [18F]MNI-1054?
[18F]MNI-1054 is a Small molecule drug developed by Invicro.
Who makes [18F]MNI-1054?
[18F]MNI-1054 is developed by Invicro (see full Invicro pipeline at /company/invicro).
What development phase is [18F]MNI-1054 in?
[18F]MNI-1054 is in Phase 1.
Related
- Manufacturer: Invicro — full pipeline
- Compare: [18F]MNI-1054 vs similar drugs
- Pricing: [18F]MNI-1054 cost, discount & access